ASX:IPD ImpediMed (IPD) Stock Price, News & Analysis → Watch this FREE trading tutorial while it’s still available (From InvestorPlace) (Ad) Free IPD Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.62 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield3.28%Price TargetN/A Stock AnalysisStock Analysis Get ImpediMed alerts: Email Address Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About ImpediMed Stock (ASX:IPD)ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.Read More Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. IPD Stock News HeadlinesMarch 14, 2024 | finance.yahoo.comImpediMed's (ASX:IPD) investors will be pleased with their notable 72% return over the last yearMarch 11, 2024 | msn.comSkin in the game: Which ASX director is betting on a lithium recovery?May 7, 2024 | InvestorPlace (Ad)Watch this FREE trading tutorial while it’s still availableOn Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.February 26, 2024 | benzinga.comImpedimed Stock (OTC:IPDQF) Dividends: History, Yield and DatesFebruary 20, 2024 | msn.comHow the experts are investing in healthcare-related AI and biotechFebruary 16, 2024 | msn.comScoPo’s Powerplays: ASX health stocks tumble as CSL bleeds after Phase III trial misses endpointFebruary 3, 2024 | morningstar.comImpedimed Ltd IPDNovember 19, 2023 | msn.comMarket Highlights: Wall Street sentiment remains high, 9 most innovative firms, and 5 small caps to watch todayMay 7, 2024 | InvestorPlace (Ad)Watch this FREE trading tutorial while it’s still availableOn Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.November 19, 2023 | fool.com.au2 ASX All Ords shares tumbling following leadership shakeupsNovember 3, 2023 | msn.comScoPo’s Powerplays: Who fancies 22 minutes of exercise? And ASX health stocks are up (finally)October 21, 2023 | afr.comImpediMed LimitedOctober 6, 2023 | finance.yahoo.comInvesting in ImpediMed (ASX:IPD) a year ago would have delivered you a 146% gainSeptember 1, 2023 | finance.yahoo.comAnalysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before LongAugust 29, 2023 | finance.yahoo.comThe IPD Group Limited (ASX:IPG) Annual Results Are Out And Analysts Have Published New ForecastsJuly 17, 2023 | finance.yahoo.comHere's Why We're Watching ImpediMed's (ASX:IPD) Cash Burn SituationJuly 13, 2023 | finance.yahoo.comIPD.AX - ImpediMed LimitedJuly 12, 2023 | au.finance.yahoo.comIPD.XA - ImpediMed LimitedJune 30, 2023 | msn.comScoPo’s (actually Wilkie’s) Powerplays: Inoviq soars on clinical data for breast cancer testMay 26, 2023 | msn.comScoPo’s Powerplays: ASX health stocks fall as investors fail to reward good newsApril 22, 2023 | msn.comWILSONS Maintains ImpediMed (ASX:IPD) Overweight RecommendationApril 21, 2023 | msn.comScoPo’s (actually Iain’s) Powerplays: ASX health stocks fall, Neuren’s DAYBUE drug officially rolling out in USApril 7, 2023 | finance.yahoo.comImpediMed (ASX:IPD) shareholders have earned a 40% CAGR over the last three yearsMarch 31, 2023 | msn.comScoPo’s Powerplays: ASX health stocks rise, ImpediMed surges 99% on NCCN guidelines updateMarch 27, 2023 | msn.comGuess which ASX biotech share just rocketed 86% on ‘a major validating moment’March 26, 2023 | msn.comASX Small Caps Lunch Wrap: Who else is having trouble believing their eyes this morning?March 26, 2023 | msn.comTop 10 at 10: Cancer fighters, new lithium leaders, and a lucrative takeover offerSee More Headlines Receive IPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImpediMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:IPD CUSIPN/A CIKN/A Webwww.impedimed.com Phone61 7 3860 3700FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-102.5Net Income$-19,500,000.00 Net Margins-185.47% Pretax MarginN/A Return on Equity-42.36% Return on Assets-27.58% Debt Debt-to-Equity Ratio2.50 Current Ratio7.00 Quick Ratio6.23 Sales & Book Value Annual Sales$10.47 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.60 Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares2,020,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.94 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Shashi TripathiChief Operating OfficerDr. Parmjot Bains M.D.MD, Interim CEO & DirectorMr. McGregor Grant BEcC.A., FCIS, GAICD, Interim CFO & Executive DirectorMr. Dennis SchlahtSenior Vice President of R&D and TechnologyLisa PromVice President of SalesMs. Joann YaoChief Strategy OfficerDr. Steven Chen M.B.A.M.D., Chief Medical CenterMs. Leanne Ralph AAICDACIS, BBus, Company SecretaryDr. Walton A. TaylorMedical DirectorMore ExecutivesKey Competitors4DMedicalASX:4DXAdheriumASX:ADRADM Tronics UnlimitedOTCMKTS:ADMTAinosNASDAQ:AIMDWAllegra Medical TechnologiesASX:AMTView All CompetitorsInsidersJanelle DelaneyBought 568,181 shares on 3/25/2024Total: $49,999.93 ($0.09/share)Janelle DelaneyBought 581,395 shares on 3/22/2024Total: $49,999.97 ($0.09/share)Janelle DelaneyBought 1,137,634 shares on 3/4/2024Total: $100,111.79 ($0.09/share)Andrew GrantBought 100,000 shares on 2/29/2024Total: $87,000.00 ($0.87/share)Christine Emmanuel-DonnellyBought 67,857 shares on 12/13/2023Total: $9,499.98 ($0.14/share) IPD Stock Analysis - Frequently Asked Questions What other stocks do shareholders of ImpediMed own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImpediMed investors own include Bardoc Gold (BDC) and Appen (APX). This page (ASX:IPD) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyDave Ramsey Shocks Millions With US Dollar LunacyAmerican Hartford Gold GroupTrump is sounding the alarmPreserve GoldBiden’s Sneaky H.R. 5376 Is A Nightmare For Retirement SaversBirch GoldThe best inflation-proof investment DTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImpediMed Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
